Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 1;6:374. doi: 10.1038/s41392-021-00773-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Survival outcomes with mefatinib were similar for patients who received mefatinib at 60 and 80 mg but were significantly different based on brain metastatic status at presentation. Kaplan–Meier curves comparing the progression-free survival (a, c) and overall survival (b, d) of patients with advanced EGFR–mutant non-small-cell lung cancer who received mefatinib as first-line therapy at a daily dose of either 60 mg or 80 mg (a, b) or based on brain metastatic status at presentation (c, d)